Study Identifies When Weight Gain Begins After Stopping Ozempic-like Drugs

Recent research has uncovered how swiftly individuals tend to regain weight after discontinuing weight loss medications.

GLP-1 medications are recognized for their ability to assist in weight reduction by controlling blood sugar and appetite.

Ozempic, a drug within this category, has gained significant popularity. It is specifically designed for individuals with type two diabetes, as noted on its website: “Ozempic is a medicine for adults with type 2 diabetes that, along with diet and exercise, may improve blood sugar.”

The website further clarifies: “While not for weight loss, Ozempic may help you lose some weight.”

In the United States, approximately 12 percent of adults have tried GLP-1 medications, such as Ozempic and Wegovy.

Some individuals may plan to use the medication long-term, depending on the side effects, to achieve their desired weight.

However, a study discovered that most people cease using these injectable drugs around the one-year mark or when their weight loss plateaus. Therefore, even with a positive response, long-term usage is unlikely.

The recent study in BMC Medicine has pinpointed the exact timeframe when individuals begin to regain weight after stopping GLP-1 and similar weight-loss medications, which is a concern for those considering discontinuation.

Researchers Xiaoling Cai, Linong Ji, and their team from Peking University People’s Hospital conducted a worldwide meta-analysis, examining 11 studies on how patients’ weight fluctuated after halting anti-obesity medications (AOMs).

The study analyzed data from 1,574 individuals who were under treatment and 893 in control groups.

Weight regain was assessed by monitoring body weight and BMI post-medication.

Out of the 11 studies, six concentrated on GLP-1 receptor agonists (such as Ozempic and Wegovy), while one examined dual GLP-1/GIP drugs like Mounjaro.

The findings showed that ‘significant’ weight regain commenced eight weeks after ceasing the use of weight-loss drugs.

Participants, on average, gained 1.5 kilograms (3.3 pounds) at this stage.

Weight gain continued to rise until the 20-week mark, where the average increase was 2.5 kilograms (5.5 pounds), after which it began to stabilize.

Despite this, patients still maintained a weight reduction compared to their initial weight.

Even a year after stopping the medication, individuals weighed less than before starting the treatment.

Researchers aim to continue monitoring patients over a longer duration to gain a deeper understanding of what affects weight changes post-treatment, considering factors such as diabetes status, lifestyle habits, and the specific type of weight-loss drug used.

Consequently, while weight regain is possible, discontinuing the medication should not be a source of anxiety.

Novo Nordisk, the manufacturer of Ozempic and Wegovy, reiterated that Ozempic is not meant for weight loss and shared the outcomes of their own trial with UNILAD.

A spokesperson commented: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped. Clinical experts consulted by Novo Nordisk view obesity as a chronic disease that should be managed similar to long-term health conditions such as diabetes and hypertension.

“These results are in line with other Glucagonlike peptide-1 receptor agonists (GLP-1 RAs) researched for weight loss.

“Eligible patients for Wegovy® use should be referred to specialist weight management services by their GP or local pharmacists. These services provide knowledge, tools, and support for successful, sustainable weight loss with a focus on promoting long-term health and wellbeing. Weight management services typically include teams of dietitians, dietic support workers, clinical psychologists, counsellors, doctors, and nutritionists available to support on the weight loss journey.”

Share your love